YieldMax NVDA Option Income Strategy ETF vs SELLAS Life Sciences Group Inc. Common Stock — how do they compare? YieldMax NVDA Option Income Strategy ETF trades at $12.76 (market cap $1.45B), while SELLAS Life Sciences Group Inc. Common Stock trades at $11.22 (market cap $2.27B). The key difference: SELLAS Life Sciences Group Inc. Common Stock is the larger of the two by market cap, and SELLAS Life Sciences Group Inc. Common Stock is trading nearer its 52-week high, YieldMax NVDA Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| NVDY | SLS | |
|---|---|---|
Market Cap | $1.45B | $2.27B |
Volume | 1,943,739 | 4,179,659 |
Sector | Income / Options Overlay | Health |
52-Week High | $17.21 | $15.46 |
52-Week Low | $11.58 | $1.39 |
Typical Hold Time | 43 Days | — |
Enterprise Value | — | $2.14B |
Signals from Pluang's Aura AI — not financial advice
NVDY, the YieldMax NVDA Option Income Strategy ETF, trades at $13.01, down slightly by 0.31% on the day. The technical outlook is bullish based on moving averages, though oscillators are neutral and RSI levels suggest overbought conditions. The fund generates weekly dividend distributions, with recent payouts ranging from $0.08 to $0.12, but faces criticism for potential net asset value erosion and capped upside participation relative to its underlying asset, NVIDIA stock.
The outlook for NVDY is mixed; it offers high distribution yields but structural limitations may hinder long-term capital appreciation. Investment opportunities include income generation in a low-volatility environment, while risks involve NAV erosion and reduced upside capture if NVIDIA's volatility declines. Analyst sentiment has shifted to hold ratings, reflecting concerns over sustainability.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
NVDY is an actively managed ETF that pursues a synthetic covered call strategy on NVIDIA Corporation (NVDA) stock. The fund primarily sells call options on NVDA and invests in U.S. Treasury securities and other high-quality collateral. Its goal is to generate monthly income from the option premiums. This strategy provides exposure to the high-growth potential of NVDA while seeking to deliver a high yield, though it caps the potential capital appreciation of the stock.
Read more on NVDY →SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing therapies for cancer. Its programs include a WT1-targeting cancer immunotherapy and a selective CDK9 inhibitor.
Read more on SLS →